Aesthetic Procedure Safety in Autoimmune Diseases 2026

Autoimmune Disease and Aesthetics: Core Concepts

Autoimmune diseases are a group of chronic conditions in which the immune system erroneously attacks the body's own tissues, typically following a flare-remission cycle. From a dermatological perspective, these patients require special attention, as many autoimmune diseases affect the structure of the skin, its healing capacity, or its photosensitivity.

The most common dermatology-associated autoimmune diseases include: Systemic Lupus Erythematosus (SLE), Discoid Lupus, Sjögren's Syndrome, Systemic Sclerosis (Scleroderma), Rheumatoid Arthritis (RA), Mixed Connective Tissue Disease (MCTD), Dermatomyositis, Polymyositis, and Psoriatic Arthritis. Each of these diseases has a distinct profile in terms of skin compatibility and suitability for aesthetic procedures.

In the context of aesthetic procedures, autoimmune diseases may give rise to two fundamental risks: increased risk of complications (infection, delayed healing, wound dehiscence, atypical scarring) and triggering of disease activation (procedure-induced stress response or foreign body reaction causing disease flare). The majority of these risks can be managed to an acceptable level through proper patient selection and timing.

Systemic Lupus Erythematosus (SLE): Key Considerations for Aesthetic Procedures

SLE is one of the most common systemic autoimmune diseases, and its dermatological manifestations (butterfly erythema, photosensitivity, discoid lesions, oral ulcers) directly influence the skin treatment plan.

Core risks:

• Photosensitivity: 50–70% of SLE patients are hypersensitive to UV radiation; laser, IPL, and certain LED phototherapy treatments may trigger the Koebner phenomenon or lupus activation
• Impaired healing: Tissue repair slows during active disease phases or with high-dose corticosteroid use; wound healing is prolonged
• Immunosuppression: Patients on hydroxychloroquine, mycophenolate mofetil, or biological agents face an elevated infection risk
• Antiphospholipid syndrome: This co-existing condition in many SLE patients increases thrombosis risk; anticoagulation assessment is required for invasive procedures

Applicable procedures (during remission): Hyaluronic acid filler, botulinum toxin, mild chemical peeling (low concentration), skin boosters. Laser treatments should be evaluated after specialist consultation; they must not be performed during active disease.

Systemic Sclerosis (Scleroderma): The Most Restrictive Autoimmune Condition

Scleroderma is a connective tissue disease causing fibrosis of the skin and internal organs. It represents the most challenging autoimmune condition in the context of medical aesthetics:

• Perioral fibrosis: Tightening around the mouth (microstomia) both complicates injection access and impairs healing
• Vascular abnormalities: Raynaud's phenomenon, telangiectasias, and capillary damage increase the risk of vascular complications during injection and laser procedures
• Skin fragility: Fibrotic skin does not respond like normal skin; filler placement is unpredictable
• Impaired wound healing: Risk of necrosis is elevated due to microcirculatory dysfunction

General approach: Elective aesthetic procedures carry high risk in patients with scleroderma; only procedures aimed at symptom management (e.g., perioral botulinum toxin for microstomia-related chewing assistance) may be considered by specialist physicians with multidisciplinary approval. Cosmetic filler and laser are not routinely recommended.

Rheumatoid Arthritis (RA): A Comparatively Manageable Profile

Rheumatoid arthritis is an autoimmune disease primarily affecting the joints; while not a skin disease per se, the medications used affect the safety of aesthetic procedures:

• Methotrexate: Suppresses mucosal renewal; delayed healing may occur after deep chemical peeling
• Biological agents (anti-TNF, anti-IL-6): Increase infection risk; healing may be compromised if complications requiring surgery arise
• Corticosteroids: Long-term use causes skin atrophy, easy bruising, and delayed healing
• NSAIDs: Prolong bleeding time; it is recommended to discontinue them at least 5–7 days before injections

Applicable procedures: In RA patients in remission with stable immunosuppressive dosing, botulinum toxin, HA filler, skin boosters, oxygen therapy, and low-level laser treatments can be performed with physician evaluation. Pre-procedure rheumatology consultation is recommended.

Sjögren's Syndrome: Skin Dryness and Special Considerations

Sjögren's syndrome primarily affects the exocrine glands (salivary, lacrimal, and sweat glands), resulting in severe xerosis (skin dryness). Key aesthetic considerations include:

• Severe skin dryness delays barrier repair after chemical peeling and ablative laser; downtime is prolonged
• Dry eye (xerophthalmia) poses an additional risk in periorbital botulinum toxin and filler procedures; procedures affecting ocular lubrication are inadvisable
• Deep hydration-focused procedures (Profhilo, skin boosters, oxygen therapy) are particularly indicated; skin barrier support is the primary objective
• Immunosuppressive use should be evaluated; hydroxychloroquine carries a mild antiplatelet effect

Vitiligo: Koebner Effect and Procedure Selection

Vitiligo is an autoimmune condition characterised by melanocyte loss; it carries no systemic complications, but the Koebner phenomenon must be considered when selecting aesthetic procedures:

Koebner phenomenon: New vitiligo plaques may develop in response to trauma or inflammation. For this reason, procedures that cause skin injury (ablative laser, microneedling, deep peeling) should not be applied to affected or at-risk areas during periods of active vitiligo. Standard procedures can be performed during stable vitiligo phases and in anatomically distant areas. Specialised laser therapy (excimer 308 nm) and phototherapy for repigmentation constitute a separate treatment category indicated for vitiligo.

Dermatomyositis: Photosensitivity and Metabolic Considerations

Dermatomyositis is an inflammatory myopathy affecting the skin and muscle tissue. Clinical features include Gottron's papules, heliotrope erythema, and photo-aggravated rash. From an aesthetic procedure standpoint, the following should be considered:

• High photosensitivity similar to SLE; UV-based and light-based treatments are contraindicated
• Elective procedures should be deferred during active disease and high-dose corticosteroid periods
• Application of botulinum toxin to facial muscles weakened by myopathy requires mandatory functional assessment
• Given the frequent association with malignancy, oncology follow-up takes priority during active disease

Procedure Safety Summary Table: Autoimmune Disease × Procedure Matrix

This table serves as a general guide; specialist assessment is always required for individual decision-making.

Criteria for Deferral During Active Disease Phases

In patients with autoimmune diseases, all elective aesthetic procedures should be deferred in the following circumstances:

• Disease activation: elevated acute phase reactants (raised CRP, ESR), concurrent flare signs
• Recent increase in immunosuppressive dosing (within the past 4–6 weeks): corticosteroid pulse therapy, initiation of a new biological agent
• Active infection or febrile episode
• Active cutaneous involvement with compromised skin integrity (discoid lupus lesion activation, scleroderma ulcers)
• Thrombocytopenia (platelet count < 100,000/µL), bleeding diathesis
• Periods requiring immunosuppressive interruption prior to elective surgery (per rheumatologist's plan)

Immunosuppressive Medications and Their Interaction with Aesthetic Procedures

The majority of patients with autoimmune diseases are on chronic immunosuppressive therapy. The impact of the most commonly used medications on aesthetic procedure safety:

• Corticosteroids: Skin atrophy, delayed wound healing, increased infection risk; proportional to dose
• Methotrexate: Suppresses mucosal renewal; increases the risk of deep peeling; peri-procedural folate supplementation is recommended
• Hydroxychloroquine: Antiplatelet effect; may slightly prolong bleeding time; generally manageable
• Anti-TNF agents (adalimumab, etanercept): Infection risk; brief pre-procedure interruption is subject to rheumatologist decision
• JAK inhibitors (tofacitinib, baricitinib): A newer class; infection and thrombosis risk; comprehensive perioperative assessment required
• Mycophenolate mofetil: May reduce mucosal and skin regenerative capacity; caution with ablative procedures

Our Approach to Patients with Autoimmune Diseases at Virtuana Clinic

At Virtuana Clinic in Izmit/Kocaeli, a dedicated evaluation framework is applied for patients with autoimmune diseases:

1. Detailed medical history: Disease type, duration, history of activation, all current medications, and recent laboratory results
2. Rheumatologist / relevant specialist liaison: Coordination with the treating physician for procedure approval when required
3. Individual risk–benefit assessment: Personalised decision-making that takes into account each patient's disease profile and procedure plan
4. Low-risk procedure prioritisation: Whenever possible, the least invasive approach with the best safety profile is chosen
5. Enhanced follow-up: More frequent check-ins during the post-procedure complication window
6. Clear right to decline: If safety requirements cannot be met, the procedure is not performed

If you have an autoimmune disease and are considering an aesthetic procedure, we recommend sharing your condition openly as a first step. Transparent information exchange directly determines both your safety and the outcome of your treatment.

This article is for informational purposes only. Please consult a qualified physician for treatment decisions.